Mar 06th 2013 - Edison Investment Research today published a report on Vernalis (VER.L, LSE:VER, LON:VER) entitled "First Cough/cold Milestone". In summary, the report says:
Vernalis has paid out its first milestone to Tris Pharma, which marks the successful “proof of concept” for the first collaboration programme (CCP-01). The alliance with Tris Pharma aims to develop up to six extended release cough/cold products for the US prescription market. The timings suggest an NDA for CCP-01 could be filed mid-14. The creation of a portfolio of extended release products is a major element of the strategy to achieve sustainable profitability. Further in-licensing efforts should now focus on products that complement the seasonality of this emerging portfolio.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »